All influenza vaccines are made by growing influenza virusparticles in chicken eggs before treating them in a way to kill (inactivate) or weaken the viruses.
The first clear hint of targeted therapy's potential came in late 2003, when researchers at the German firm Boehringer Ingelheim reported that its hepatitis C protease inhibitor lowered the quantity of virusparticles by roughly 99.9% in eight patients in two days of treatment, beating what interferon can accomplish in that time period.
Novavax's vaccines utilize what are called virus-like particles--genetically engineered molecules designed to train the immune system to recognize a particular virus.